Get the Stockscreener App
1.22
6.09%
0.07
After Hours:
1.23
0.01
+0.82%
Neurosense Therapeutics Ltd stock is traded at $1.22, with a volume of 2.12M.
It is up +6.09% in the last 24 hours and up +8.93% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$1.15
Open:
$1.21
24h Volume:
2.12M
Relative Volume:
3.12
Market Cap:
$34.06M
Revenue:
-
Net Income/Loss:
$-13.76M
P/E Ratio:
-1.3118
EPS:
-0.93
Net Cash Flow:
-
1W Performance:
+3.39%
1M Performance:
+8.93%
6M Performance:
+11.93%
1Y Performance:
-5.43%
1-Day Range:
$1.18
$1.275
1-Week Range:
$1.10
$1.98
52-Week Range:
$0.80
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.22 | 34.06M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
Custom strategy builders for tracking NeuroSense Therapeutics Ltd. Equity Warrant2025 Momentum Check & Real-Time Chart Pattern Alerts - Newser
Applying Wyckoff theory to NeuroSense Therapeutics Ltd. Equity Warrant stockMarket Growth Report & Free Long-Term Investment Growth Plans - Newser
What earnings revisions data tells us about NeuroSense Therapeutics Ltd. Equity WarrantMarket Performance Summary & Technical Confirmation Trade Alerts - Newser
What machine learning models say about NeuroSense Therapeutics Ltd. Equity WarrantJuly 2025 Pullbacks & Risk Adjusted Buy/Sell Alerts - Newser
can neurosense therapeutics ltd. recover in the next quarterJuly 2025 Closing Moves & High Accuracy Swing Entry Alerts - Newser
What MACD and RSI say about NeuroSense Therapeutics Ltd.July 2025 WrapUp & Entry Point Strategy Guides - Newser
Detecting support and resistance levels for NeuroSense Therapeutics Ltd.Portfolio Risk Report & Weekly High Conviction Trade Ideas - Newser
What the charts say about NeuroSense Therapeutics Ltd. Equity Warrant todayPortfolio Risk Report & Fast Gain Swing Alerts - Newser
Is NeuroSense Therapeutics Ltd. stock reversal real or fakeCPI Data & Community Consensus Stock Picks - Newser
Does NeuroSense Therapeutics Ltd. qualify in momentum factor screeningMarket Growth Report & Community Consensus Picks - Newser
Understanding NeuroSense Therapeutics Ltd.’s price movementJuly 2025 Review & Weekly Watchlist for Consistent Profits - Newser
NeuroSense Therapeutics Ltd. Equity Warrant stock trend outlook and recovery pathPortfolio Risk Report & Weekly Chart Analysis and Trade Guides - Newser
Health Care Stocks Tumble While Neurosense Defies The Drop - Finimize
Is NeuroSense Therapeutics Ltd. Equity Warrant still worth holding after the dipWeekly Profit Report & Community Trade Idea Sharing - Newser
Sector Update: Health Care - MarketScreener
NeuroSense Reports Positive Initial Results for Alzheimer’s Drug Candidate - TipRanks
Neurosense Therapeutics Shares Up After Initial Phase 2 Data of Alzheimer's Disease Treatment Show Enhanced Neuroplasticity - MarketScreener
Neurosense's drug candidate shows early signals of benefit in Alzheimer's patient-derived neurons - MarketScreener
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons - PR Newswire
NeuroSense Therapeutics Announces Annual General Meeting for September 2025 - MSN
Automated trading signals detected on NeuroSense Therapeutics Ltd. Equity Warrant - Newser
Published on: 2025-09-10 05:46:58 - Newser
Combining price and volume data for NeuroSense Therapeutics Ltd.Market Trend Report & Reliable Price Breakout Alerts - Newser
Will earnings trigger a reversal in NeuroSense Therapeutics Ltd.Portfolio Risk Summary & Pattern Based Trade Signal System - Newser
How to build a dashboard for NeuroSense Therapeutics Ltd. Equity Warrant stockJuly 2025 Fed Impact & Weekly High Return Stock Forecasts - Newser
Will a bounce in NeuroSense Therapeutics Ltd. Equity Warrant offer an exitGap Down & Long-Term Safe Investment Plans - Newser
Full technical analysis of NeuroSense Therapeutics Ltd. Equity Warrant stockShort Setup & Accurate Buy Signal Alerts - Newser
Can momentum traders help lift NeuroSense Therapeutics Ltd.Take Profit & Verified Swing Trading Watchlist - Newser
Top chart patterns to watch in NeuroSense Therapeutics Ltd. Equity Warrant2025 Volatility Report & Growth Focused Entry Point Reports - Newser
Why is NeuroSense Therapeutics Ltd. stock going downTrade Performance Summary & Free Real-Time Volume Trigger Notifications - Lancaster City Council
NeuroSense Therapeutics Secures $500,000 in Premium Private Placement - MSN
Is NeuroSense Therapeutics Ltd. stock a value trap2025 Sector Review & Daily Growth Stock Tips - Lancaster City Council
Does NeuroSense Therapeutics Ltd. Equity Warrant have strong fundamentals2025 Trade Ideas & Community Verified Watchlist Alerts - Lancaster City Council
Will NeuroSense Therapeutics Ltd. face regulatory challengesWeekly Trend Recap & Daily Growth Stock Investment Tips - Lancaster City Council
Can NeuroSense Therapeutics Ltd. grow without dilutionJuly 2025 Reactions & Low Drawdown Momentum Ideas - Lancaster City Council
Chart based analysis of NeuroSense Therapeutics Ltd. Equity Warrant trendsTrade Signal Summary & Weekly High Conviction Trade Ideas - Newser
Multi asset correlation models including NeuroSense Therapeutics Ltd.2025 Geopolitical Influence & Reliable Breakout Stock Forecasts - Newser
Is NeuroSense Therapeutics Ltd. Equity Warrant’s ROE strong enough2025 Big Picture & Capital Efficient Trade Techniques - beatles.ru
Is it time to cut losses on NeuroSense Therapeutics Ltd.July 2025 Weekly Recap & Fast Gain Stock Trading Tips - Newser
Is NeuroSense Therapeutics Ltd. Equity Warrant part of any ETFJuly 2025 Recap & AI Driven Stock Reports - beatles.ru
NeuroSense Therapeutics Ltd. Facing Inflection Point in Trend AnalysisQuarterly Risk Review & Fast Gaining Stock Strategy Reports - beatles.ru
NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis - MarketBeat
Using AI based signals to follow NeuroSense Therapeutics Ltd. Equity WarrantEarnings Beat & Weekly High Potential Stock Alerts - Newser
Can NeuroSense Therapeutics Ltd. Equity Warrant outperform under higher oil pricesDay Trade & Reliable Price Action Trade Plans - خودرو بانک
Is NeuroSense Therapeutics Ltd. forming higher highs and higher lowsProduct Launch & Low Risk Entry Point Tips - خودرو بانک
Is NeuroSense Therapeutics Ltd. a turnaround story2025 Buyback Activity & Smart Swing Trading Techniques - خودرو بانک
Will NeuroSense Therapeutics Ltd. outperform tech stocks2025 EndofYear Setup & Stock Portfolio Risk Management - خودرو بانک
Analyzing net buyer seller activity in NeuroSense Therapeutics Ltd. Equity WarrantWeekly Investment Summary & Real-Time Buy Zone Alerts - Newser
Is NeuroSense Therapeutics Ltd. showing insider buyingEarnings Summary Report & Daily Chart Pattern Signal Reports - خودرو بانک
Neurosense Therapeutics shares fall 1.82% premarket after $500,000 private placement at 40% premium. - AInvest
NeuroSense Therapeutics Ltd. stock trend outlook and recovery pathDividend Hike & AI Driven Stock Price Forecasts - Newser
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):